EPS for Depomed, Inc. (DEPO) Expected At $-0.22

January 21, 2018 - By Hazel Jackson

 EPS for Depomed, Inc. (DEPO) Expected At $ 0.22
Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.34, from 0.87 in 2017Q2. It increased, as 23 investors sold Depomed, Inc. shares while 40 reduced holdings. 24 funds opened positions while 52 raised stakes. 56.42 million shares or 3.13% more from 54.71 million shares in 2017Q2 were reported.
Goldman Sachs Gp Incorporated reported 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Moreover, Quantitative Mngmt Ltd Limited Liability Company has 0.01% invested in Depomed, Inc. (NASDAQ:DEPO). Wells Fargo And Communication Mn invested 0% in Depomed, Inc. (NASDAQ:DEPO). Price T Rowe Associate Incorporated Md holds 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO) for 856,771 shares. Fincl Bank Of Montreal Can reported 0% stake. Envestnet Asset has 61 shares. Ls Invest Advsrs Limited Liability Company reported 2,353 shares. Susquehanna Intll Group Limited Liability Partnership reported 15,198 shares. Ubs Asset Mgmt Americas Incorporated owns 16,196 shares. Millennium Ltd Liability Corp stated it has 0.01% in Depomed, Inc. (NASDAQ:DEPO). Citigroup invested 0% in Depomed, Inc. (NASDAQ:DEPO). Gemmer Asset Management Ltd has 0% invested in Depomed, Inc. (NASDAQ:DEPO). Virtu Ltd Llc reported 0% in Depomed, Inc. (NASDAQ:DEPO). Philadelphia Trust holds 0% in Depomed, Inc. (NASDAQ:DEPO) or 10,000 shares. State Street Corporation has 0% invested in Depomed, Inc. (NASDAQ:DEPO).

Since December 14, 2017, it had 1 insider purchase, and 0 sales for $612,000 activity.

Analysts expect Depomed, Inc. (NASDAQ:DEPO) to report $-0.22 EPS on February, 20.They anticipate $0.50 EPS change or 69.44 % from last quarter’s $-0.72 EPS. After having $-0.25 EPS previously, Depomed, Inc.’s analysts see -12.00 % EPS growth. The stock decreased 0.26% or $0.02 during the last trading session, reaching $7.77. About 820,321 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 46.86% since January 21, 2017 and is downtrending. It has underperformed by 63.56% the S&P500.

Depomed, Inc. (NASDAQ:DEPO) Ratings Coverage

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 50 analyst reports since July 30, 2015 according to SRatingsIntel. As per Monday, September 19, the company rating was maintained by Mizuho. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Neutral” rating given on Thursday, January 7 by Mizuho. Mizuho downgraded Depomed, Inc. (NASDAQ:DEPO) rating on Tuesday, October 4. Mizuho has “Neutral” rating and $27 target. RBC Capital Markets maintained the shares of DEPO in report on Wednesday, November 8 with “Hold” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, February 23. The rating was initiated by Leerink Swann with “Outperform” on Thursday, March 10. Piper Jaffray maintained it with “Hold” rating and $9.0 target in Friday, October 13 report. The stock of Depomed, Inc. (NASDAQ:DEPO) has “Buy” rating given on Friday, May 27 by Mizuho. RBC Capital Markets maintained Depomed, Inc. (NASDAQ:DEPO) on Monday, June 12 with “Hold” rating. The firm earned “Hold” rating on Thursday, September 14 by RBC Capital Markets.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $489.62 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: